Page 422 - Read Online

Page 18 of 22 Droste et al. J Cancer Metastasis Treat 2023;9:2 https://dx.doi.org/10.20517/2394-4722.2022.94

2020;6:116-24. DOI PubMed PMC
27. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC
5). Ann Oncol 2020;31:1623-49. DOI PubMed PMC
28. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre-
and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin
Cancer Res 2022;28:851-9. DOI PubMed PMC
29. Neven P, Rugo HS, Tolaney SM, et al. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor
receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer
Res 2021;23:87. DOI PubMed PMC
30. Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-
positive breast cancer. Cancer Res 2016;76:2301-13. DOI
31. Pandey K, An HJ, Kim SK, et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int J Cancer
2019;145:1179-88. DOI PubMed PMC
32. Portman N, Alexandrou S, Carson E, Wang S, Lim E, Caldon CE. Overcoming CDK4/6 inhibitor resistance in ER-positive breast
cancer. Endocr Relat Cancer 2019;26:R15-30. DOI PubMed
33. Gao X, Leone GW, Wang H. Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res 2020;148:147-69. DOI PubMed
34. Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006;9:23-32. DOI PubMed
35. Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012;22:438-51. DOI
PubMed PMC
36. Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER
signaling and dependence. Oncogene 2017;36:2255-64. DOI PubMed PMC
37. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and
therapeutic implications in breast cancer. Breast Cancer Res 2011;13:224. DOI PubMed PMC
38. Wander SA, Han HS, Zangardi ML, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast
cancer: a multicenter experience. J Natl Compr Cancer Netw 2021:1-8. DOI PubMed
39. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single
agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res 2017;23:5218-24. DOI
40. Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib
after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable
or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. JCO 2022;40:LBA1004.
DOI
41. Hermida-Prado F, Jeselsohn R. The ESR1 mutations: from bedside to bench to bedside. Cancer Res 2021;81:537-8. DOI PubMed
42. Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-
positive breast cancer. Breast Cancer Res 2021;23:85. DOI PubMed PMC
43. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in
breast cancer. Nat Rev Clin Oncol 2015;12:573-83. DOI PubMed PMC
44. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated
advanced estrogen receptor-positive breast cancer. Clin Cancer Res 2014;20:1757-67. DOI PubMed PMC
45. Turner NC, Swift C, Kilburn L, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone
receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res 2020;26:5172-7.
DOI PubMed
46. Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast
cancer. J Clin Oncol 2016;34:2961-8. DOI PubMed
47. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-
45. DOI PubMed PMC
48. Schiavon G, Hrebien S, Garcia-Murillas I, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during
therapy for metastatic breast cancer. Sci Transl Med 2015;7:313ra182. DOI PubMed PMC
49. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep
sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68. DOI PubMed
50. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med
2013;368:1199-209. DOI PubMed
51. Turner NC, Ro J, André F, et al. Palbociclib in Hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19.
DOI
52. Berger F, Marce M, Delaloge S, et al. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of
palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-
negative metastatic breast cancer patients: study design of PADA-1. BMJ Open 2022;12:e055821. DOI PubMed PMC
53. Bidard F, Hardy-bessard A, Bachelot T, et al. Abstract GS3-05: fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib
upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: results of PADA-1, a UCBG-GINECO
randomized phase 3 trial. Cancer Res 2022;82:GS3-05. DOI